Jack B. Nielsen, M.S.
Managing Partner

Jack B. Nielsen is a Managing Partner of Vivo Capital. Prior to joining Vivo, Jack worked within the Novo A/S organization and its venture activities since 2001 in several roles, most recently as a Senior Partner. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco, where he established the firm’s U.S. office. Jack currently serves as a member of the Board of Directors of Aligos Therapeutics, ALX Oncology, Harmony Biosciences, Instil Bio, IO Biotech. He previously served on the board of directors of publicly-traded companies Reata Pharmaceuticals, Akebia Therapeutics, Merus, B.V and Apollo Endosurgery. He was also a member of the board of directors of a number of private companies including Alios Biopharma, Anokion, NeoMend, Procept Biorobotics, ProteinSimple, Tobira Therapeutics, and Unchained Labs.

Jack holds a Master of Science, Chemical Engineering and Master in Management of Technology from The Technical University of Denmark, Copenhagen.